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Summary
The MUC1 oncoprotein is aberrantly overexpressed by most human carcinomas. The present work demonstrates that
MUC1 associates with the p53 tumor suppressor, and that this interaction is increased by genotoxic stress. The MUC1
cytoplasmic domain binds directly to p53 regulatory domain. Chromatin immunoprecipitation assays demonstrate that
MUC1 coprecipitates with p53 on the p53-responsive elements of the p21 gene promoter and coactivates p21 gene tran-
scription. Conversely, MUC1 attenuates activation of Bax transcription. In concert with these results, MUC1 promotes
selection of the p53-dependent growth arrest response and suppresses the p53-dependent apoptotic response to DNA
damage. These findings indicate that MUC1 regulates p53-responsive genes and thereby cell fate in the genotoxic
stress response.S I G N I F I C A N C E
The MUC1 oncoprotein is aberrantly overexpressed in about 800,000 of the 1.3 million tumors diagnosed annually in the United
States. MUC1 localizes to mitochondria and blocks activation of the intrinsic apoptotic pathway. The present studies demonstrate
that MUC1 binds directly to the p53 tumor suppressor and coactivates DNA damage-induced transcription of the p21 gene. By
contrast, MUC1 attenuates activation of the proapoptotic Bax gene. The demonstration that MUC1 both promotes the p53-depen-
dent growth arrest response and suppresses the p53-dependent apoptotic response to DNA damage further indicates that overex-
pression of MUC1 by human tumors could be of importance to cell fate selection in the activation of p53 by genotoxic anticancer
agents.Introduction
The human DF3/MUC1 integral membrane glycoprotein is ex-
pressed on the apical borders of normal secretory epithelial
cells (Kufe et al., 1984). With transformation and loss of polar-
ity, MUC1 is found at high levels in the cytosol and over the
entire surface of carcinoma cells (Kufe et al., 1984; Perey et al.,
1992). MUC1 is expressed as a heterodimer following synthe-
sis as a single polypeptide and cleavage in the endoplasmic
reticulum (Ligtenberg et al., 1992). The MUC1 N-terminal sub-
unit (N-ter) consists of variable numbers of 20 amino acid tan-
dem repeats that are modified by O-glycans (Gendler et al.,
1988; Siddiqui et al., 1988). MUC1 N-ter is tethered to the cell
membrane through dimerization with the C-terminal subunit
(C-ter), which consists of a 58 amino acid extracellular domain,
a 28 amino acid transmembrane domain, and a 72 amino acid
cytoplasmic tail (Merlo et al., 1989). MUC1 interacts with mem-
bers of the ErbB family (Li et al., 2001b, 2003c; Schroeder et
al., 2001) and is targeted to the nucleus and mitochondria (Li
et al., 2003c; Ren et al., 2004). MUC1 also associates with
β-catenin (Yamamoto et al., 1997), and this interaction is regu-
lated by GSK3β-, Src-, and PKCδ-mediated phosphorylation of
the MUC1 cytoplasmic domain (MUC1-CD) (Li et al., 1998,
2001a, 2003a, 2001b; Ren et al., 2002b). Overexpression of
MUC1 is sufficient to confer transformation (Huang et al., 2003;CANCER CELL : FEBRUARY 2005 · VOL. 7 · COPYRIGHT © 2005 ELSEVIERLi et al., 2003b; Schroeder et al., 2004) and to attenuate oxida-
tive and genotoxic stress-induced apoptosis (Ren et al., 2004;
Yin et al., 2004; Yin and Kufe, 2003).
The p53 tumor suppressor functions in the cellular response
to stress by inducing growth arrest, DNA repair, senescence,
differentiation, or apoptosis (Levine, 1997). Genotoxic stress,
oxidative damage, hypoxia, nucleotide depletion, heat shock,
and oncogene expression are associated with stabilization of
p53 and induction of p53-mediated transcription. Selective
transactivation of p53 target genes dictates the induction of
apoptosis or a growth arrest and repair response (Chao et al.,
2000; Jimenez et al., 2000). Genes encoding death receptors
Fas/CD95 and DR5 (Muller et al., 1998; Wu et al., 1997) or
proapoptotic effectors such as Bax, Noxa, and Puma (Miya-
shita and Reed, 1995; Oda et al., 2000a; Yu et al., 2001) contrib-
ute to the induction of a p53-dependent apoptotic response.
Alternatively, the growth arrest response to p53 activation is
mediated in large part by induction of the p21 gene (El-Deiry
et al., 1993). p21 plays a role in promoting cell cycle pro-
gression and preventing apoptosis (Asada et al., 1999; Dong
et al., 2004; Dupont et al., 2003; Weiss, 2003; Zhang et al.,
2003). The choice of cell fate is influenced by growth factor
stimulation, proliferation status, and extent of damage (Vous-
den and Lu, 2002; Wahl and Carr, 2001). Promoter selectivity
for p53-induced apoptosis is also influenced by phosphoryla-INC. DOI 10.1016/j.ccr.2005.01.008 167
A R T I C L EFigure 1. MUC1 associates with p53
A: Lysates from HCT116/vector and HCT116/MUC1 cells were immunopreci-
pitated with anti-p53. The precipitates were analyzed by immunoblotting
with anti-MUC1 C-ter, anti-MUC1 N-ter, and anti-p53 (left). Anti-p53 and
control IgG immunoprecipitates from ZR-75-1 cells were immunoblotted
with the indicated antibodies (right). WCL, whole cell lysate.
B and C: HCT116/MUC1 (B) and ZR-75-1 (C) cells were treated with 50 or
100 M cisplatin (CDDP; left) or etoposide (right) for 24 hr. Lysates were168tion of p53 on serines 20 and 46 (Jack et al., 2002; Oda et al.,
2000b) and by interactions between p53 and members of the
ASPP family (Samuels-Lev et al., 2001), the JMY p300 binding
protein (Shikama et al., 1999), the E2F transcription factor
(Hsieh et al., 2002), and the p53 family members p73/p63 (Flo-
res et al., 2002). Although certain insights are thus available
regarding the signals that activate p53-mediated apoptosis,
less is known about the mechanisms responsible for selection
of the p53- and p21-dependent growth arrest response.
The present results demonstrate that MUC1 binds directly
to p53 and promotes p53-dependent cell fate selection of the
growth arrest and survival responses to genotoxic anticancer
agents.
Results
MUC1 associates with p53
To investigate whether MUC1 associates with p53, lysates
from HCT116/vector and HCT116/MUC1 cells were immuno-
precipitated with anti-p53. Immunoblot analysis of the precipi-
tates with anti-MUC1 C-ter (reacts with the C-terminal 17
amino acids of the MUC1 cytoplasmic domain [MUC1-CD])
showed that thew23 kDa MUC1 C-ter coprecipitates with p53
(Figure 1A, left). In contrast, there was no detectable MUC1
N-ter in the anti-p53 immunoprecipitates (Figure 1A, left). Sim-
ilar studies performed on human ZR-75-1 breast cancer cells
confirmed coimmunoprecipitation of p53 and MUC1 (Figure
1A, right). Densitometric scanning of the MUC1 signals ob-
tained from the whole cell lysates as compared to that after
immunoprecipitation of the lysates with anti-p53 indicate that
4% and 5% of total MUC1 C-ter associates with p53 in
HCT116/MUC1 and ZR-75-1 cells, respectively. Treatment of
HCT116/MUC1 cells with cisplatin or etoposide resulted in an
increase in the association of p53 and MUC1 (Figure 1B). In-
creased binding of endogenous MUC1 and p53 was also found
in ZR-75-1 cells treated with cisplatin (Figure 1C, left) or etopo-
side (Figure 1C, right). Similar results were obtained with hu-
man MCF-7 breast and LNCaP prostate cancer cells (Supple-
mental Figures S1A and S1B). These findings demonstrate that
MUC1 associates with p53 constitutively and that this interac-
tion is increased in the response to DNA damage.
MUC1-CD binds directly to p53
To define the sequences of MUC1-CD (amino acids 1–72) and
p53 involved in the association, we prepared vectors express-
ing wild-type and deletion mutants of both proteins (Figure 2A,
schema). Incubation of purified 35S-labeled p53 with purified
GST or GST-MUC1-CD demonstrated binding to MUC1-CD
(Figure 2A). Deletion of MUC1-CD from amino acids 9 to 46
abrogated the interaction, while MUC1-CD (1–51) was suffi-
cient to form a complex with p53 in vitro (Figure 2A). To confirm
these findings, we expressed p53 and MUC1-CD deletion mu-
tants in cells. As found in vitro, p53 formed complexes with
MUC1-CD (1–72), but not with MUC1-CD (O9–46) (Figure 2B).immunoprecipitated with IgG or anti-p53 and the precipitates were ana-
lyzed by immunoblotting with anti-MUC1 C-ter and anti-p53 (upper 2 pan-
els). Lysates were directly immunoblotted with anti-MUC1 C-ter and anti-β-
actin (lower 2 panels).CANCER CELL : FEBRUARY 2005
A R T I C L EFigure 2. MUC1-CD binds directly to the p53 reg-
ulatory domain
A: Schema depicting the structures of MUC1-
CD and p53. Highlighted on MUC1-CD are
phosphorylation sites and the β-catenin binding
site (upper panel). GST, GST-MUC1-CD (1–72), or
the indicated GST-MUC1-CD deletion mutants
were bound to glutathione agarose and incu-
bated with 35S-labeled p53. The adsorbates
were analyzed by SDS-PAGE and autoradiogra-
phy (lower panel). Input of the GST and GST-
MUC1-CD proteins was assessed by Coomassie
blue staining.
B: Anti-p53 immunoprecipitates from U2OS cells
transfected with 2 g p53 and 1 g Myc-MUC1-
CD or the indicated deletion mutants were
immunoblotted with anti-Myc (upper panel). Ly-
sates were directly immunoblotted with anti-
p53, anti-Myc, and anti-β-actin (lower 3 panels).
C: GST or GST-MUC1-CD were bound to glutathi-
one agarose and incubated with 35S-labeled
p53 or the indicated p53 deletion mutants. The
adsorbates were analyzed by SDS-PAGE and
autoradiography.
D: U2OS cells were transfected with 1 g Myc-
MUC1-CD and 2 g p53 or the indicated dele-
tion mutants. Anti-p53 (Ab-2/Ab-6) immuno-
precipitates were analyzed by immunoblotting
with anti-MUC1 C-ter (upper panel). Lysates
were directly immunoblotted with anti-MUC1
C-ter, anti-p53, and anti-β-actin (lower 3 panels).In addition, we found in vivo binding of p53 to MUC1-CD (1–51)
(Figure 2B). To define the region within p53, GST-MUC1-CD
was incubated with full-length p53 and certain deletion mu-
tants. Deletion of the p53 C terminus (amino acids 363–393)
abrogated binding to MUC1-CD (Figure 2C). In concert with
these results, MUC1-CD formed complexes with p53 (293–
393) and p53 (O1–50/O323–356) in vitro (Figure 2C). Expres-
sion of Myc-MUC1-CD and the p53 deletion mutants in cells
demonstrated that, as found in vitro, the interaction with
MUC1-CD is abrogated by expression of p53 (1–362) (Figure
2D). The results also show that MUC1-CD associates with p53
(293–393) in cells (Figure 2D). These findings indicate that
MUC1-CD (amino acids 9–46) binds directly to the p53 regula-
tory domain (amino acids 363–393).
MUC1 occupies the p53-responsive p21 gene promoter
To determine if MUC1 is present in the p53 transcription com-
plex, we performed chromatin immunoprecipitation (ChIP) as-
says on the p21 promoter with anti-MUC1 C-ter or a control
IgG. Immunoprecipitation of the two p53-responsive elementsCANCER CELL : FEBRUARY 2005(p53REs) in the p21 promoter was analyzed by semiquantita-
tive PCR. Using HCT116/MUC1 and ZR-75-1 cells, occupancy
of both p21 promoter p53REs by MUC1 was clearly detectable
in anti-MUC1, and not the control IgG, precipitates (Figure 3A,
left). By contrast, there was no detectable MUC1 associated
with a control region (CR) of the p21 promoter downstream to
the p53REs (Figure 3A, left). There was also no detectable
MUC1 associated with the p21 proximal promoter (PP) (Figure
3A, right). To determine if MUC1 occupies the p21 promoter
with p53, the anti-MUC1 complexes were released, reimmuno-
precipitated with anti-p53, and then analyzed by PCR (Re-
ChIP). The results show that anti-p53 precipitates the p21
p53REs after their release from anti-MUC1, indicating that
MUC1 occupies these elements with p53 (Figure 3B). A kinetic
analysis after treatment of HCT116/MUC1 and ZR-75-1 cells
with cisplatin or etoposide demonstrated that MUC1 occu-
pancy of p21 p53RE2 increases in response to DNA damage
and reaches maximal levels at 8–12 hr of drug exposure (Figure
3C). Moreover, as expected from other work (Espinosa et al.,
2003), treatment of HCT116/vector cells with cisplatin or eto-169
A R T I C L EFigure 3. MUC1 C-ter occupies p53-responsive
elements in the p21 promoter
A: Soluble chromatin from HCT116/MUC1 and
ZR-75-1 cells was immunoprecipitated with anti-
MUC1 C-ter or a control IgG. The final DNA ex-
tractions were amplified by PCR using primers
that cover the indicated p53-response ele-
ments (p53REs; −2281 to −2262 and −1395 to
−1376), a control region (CR), or the proximal
promoter (PP; TATA box located at −46 to −43)
region of the p21 gene.
B: In Re-ChIP experiments, soluble chromatin
from HCT116/MUC1 or ZR-75-1 cells was immu-
noprecipitated with anti-MUC1 C-ter, eluted
with DTT, diluted with Re-ChIP buffer, reimmuno-
precipitated with anti-p53, and analyzed for the
indicated p21 promoter sequences.
C: HCT116/MUC1 and ZR-75-1 cells were treated
with 50 M cisplatin or etoposide for the indi-
cated times. Soluble chromatin was immuno-
precipitated with anti-MUC1 C-ter and ana-
lyzed for p21 p53RE2 sequences.
D: HCT116/MUC1 and HCT116/vector cells (left)
or ZR-75-1/vector and ZR-75-1/MUC1siRNA
(right) were left untreated or treated with 50 M
cisplatin or etoposide for 8 hr. Soluble chromatin
was immunoprecipitated with the indicated an-
tibodies. The precipitates were analyzed for p21
p53RE2 promoter sequences.poside increased p53 occupancy of the p21 p53RE2 (Figure
3D, left). However, occupancy of the p21 p53RE2 by p53 was
higher constitutively and after DNA damage in HCT116/MUC1
cells (Figure 3D, left). The CREB binding protein (CBP) func-
tions as a histone acetyltransferase and coactivator of tran-
scription. MUC1 expression was associated with an increase
in CBP occupancy of the p21 p53RE2, indicating that MUC1
is associated with recruitment of CBP to the p53 transcription
complex (Figure 3D, left). In addition, occupancy of the p21
promoter by the histone deacetylase HDAC1 was decreased in
the response of HCT116/MUC1 cells to cisplatin or etoposide
as compared to that found in HCT116/vector cells (Figure 3D,
left). Acetylation of histone H4 was also more pronounced on
the p21 promoter in MUC1-positive, as compared to MUC1-
negative, HCT116 cells (Figure 3D, left). ChIP studies of the
p21 promoter in ZR-75-1/vector cells, which express endoge-
nous MUC1, and MUC1-negative ZR-75-1/MUC1siRNA cells
further demonstrated that MUC1 increases p53 and CBP occu-
pancy, decreases HDAC1 occupancy, and increases histone
H4 acetylation (Figure 3D, right). These findings indicate that
endogenous, as well as exogenous, MUC1 is detectable on
the p53REs in the p21 promoter, and that MUC1 occupancy is
associated with increased acetylation of histone H4.
MUC1 occupies the Bax proximal promoter
To assess binding of MUC1 to other p53-responsive genes,
ChIP analyses were performed on the p53RE in the Bax pro-
moter (Figure 4A). The results show that p53, and not MUC1,170occupancy of the Bax p53RE is detectable in HCT116/MUC1
and ZR-75-1 cells (Figure 4A, left). Similar results were ob-
tained after treatment of these cells with cisplatin or etoposide
(data not shown). In contrast, p53 and MUC1 occupancy of
the Bax proximal promoter (PP) was detectable in both
HCT116/MUC1 and ZR-75-1 cells (Figure 4A, right). The results
also show that anti-p53 precipitates the Bax proximal promoter
after release from anti-MUC1 (Figure 4B, left). An antibody
against the TATA binding protein (TBP) also precipitated the
Bax proximal promoter after release from anti-MUC1 (Figure
4B, right), indicating that MUC1 occupies this region with the
basal transcription apparatus. MUC1 occupancy of the Bax
proximal promoter was increased through 4–6 hr and maximal
at 6–12 hr after treatment with cisplatin or etoposide (Figure
4C). Analysis of the Bax proximal promoter following treatment
with cisplatin or etoposide also demonstrated that MUC1 ex-
pression is associated with (1) increases in p53 binding and (2)
decreases in occupancy of TFIIB and TAFII250, but not TBP
(Figure 4D). These findings indicate that MUC1 occupies the
Bax proximal promoter with p53 and interferes with assembly
of the basal transcription apparatus in the DNA damage re-
sponse.
MUC1-CD regulates transactivation
of the p21 and Bax promoters
To determine if MUC1 affects activation of the p21 promoter,
HCT116/vector and HCT116/MUC1 cells were transfected withCANCER CELL : FEBRUARY 2005
A R T I C L EFigure 4. MUC1 C-ter occupies the proximal pro-
moter in the Bax gene
A: Soluble chromatin from HCT116/MUC1 and
ZR-75-1 cells was immunoprecipitated with anti-
MUC1 C-ter or a control IgG. The final DNA ex-
tractions were amplified by PCR using primers
that cover a control region (CR), the p53-
response element (p53RE; −474 to −465), or the
proximal promoter (PP; TATA box located at
−398 to −395) region of the Bax gene.
B: In Re-ChIP experiments, soluble chromatin
from HCT116/MUC1 or ZR-75-1 cells was immu-
noprecipitated with anti-MUC1 C-ter, eluted
with DTT, diluted with Re-ChIP buffer, reimmuno-
precipitated with anti-p53 or anti-TBP, and ana-
lyzed for Bax CR and PP sequences.
C: HCT116/MUC1 and ZR-75-1 cells were treated
with 50 M cisplatin or etoposide for the indi-
cated times. Soluble chromatin was immuno-
precipitated with anti-MUC1 C-ter and ana-
lyzed for Bax PP sequences.
D: HCT116/MUC1 and HCT116/vector cells (left)
or ZR-75-1/vector and ZR-75-1/MUC1siRNA
(right) were left untreated or treated with 50 M
cisplatin or etoposide for 8 hr. Soluble chromatin
was immunoprecipitated with the indicated an-
tibodies. The precipitates were analyzed for Bax
PP sequences.a p21 promoter-Luc reporter vector (p21-Luc). Basal levels of
p21 promoter activity were increased in HCT116/MUC1 as
compared to HCT116/vector cells (Figure 5A, left). In addition,
cisplatin- or etoposide-induced activation of p21-Luc was en-
hanced as a result of MUC1 expression (Figure 5A, left). For
comparison, similar studies were performed with the Bax pro-
moter-Luc reporter (Bax-Luc). In contrast to p21-Luc, basal
and DNA damage-induced levels of Bax-Luc activity were de-
creased by MUC1 expression (Figure 5A, right). Similar results
were obtained with the ZR-75-1/vector and ZR-75-1/MUC1
siRNA cells (Figure 5B). Immunoblot analysis of lysates from
control and cisplatin- or etoposide-treated HCT116 cells dem-
onstrated that constitutive and drug-induced expression of p21
is increased in HCT116/MUC1, as compared to HCT116/vec-
tor, cells (Figure 5C). By contrast, levels of Bax were attenuated
in control and cisplatin- or etoposide-treated HCT116/MUC1
cells (Figure 5C). MUC1 expression was also associated with
selective increases in p21 protein in ZR-75-1 cells (Figure 5D).
These findings indicate that MUC1 selectively coactivates p21
gene transcription in the response to DNA damage.
MUC1 activates the growth arrest and survival
response to DNA damage
Consistent with the increases in p21 expression, treatment of
both HCT116/vector and HCT116/MUC1 cells with cisplatin or
etoposide resulted in G1 arrest of cell cycle progression (Sup-
plemental Figure S2A). However, the HCT116/MUC1 cells ex-
hibited greater accumulation in G1 phase than that found with
HCT116/vector cells (Supplemental Figure S2A). Additional ex-CANCER CELL : FEBRUARY 2005periments performed at 12 to 48 hr of drug exposure confirmed
that MUC1 increases the percentage of cells that exhibit G1
phase arrest (Figure 6A). Treatment of ZR-75-1/vector and ZR-
75-1/MUC1siRNA cells with cisplatin or etoposide provided
further evidence for involvement of MUC1 in conferring an
increase in the arrest of cells at G1 phase (Supplemental Figure
S2B and Figure 6B). Activation of the p53-induced growth ar-
rest response can be irreversible or associated with repair and
survival (Oren, 2003; Weiss, 2003). To distinguish between
these potential outcomes, we treated the HCT116 cells with
cisplatin or etoposide and monitored survival by colony forma-
tion. Clonogenic survival was higher for cisplatin- or etoposide-
treated HCT116/MUC1 as compared to HCT116/vector cells
(Supplemental Figure S2C and Figure 6C). Clonogenic survival
of ZR-75-1 cells following cisplatin or etoposide treatment
(Supplemental Figure S2D and Figure 6D) was also increased
by MUC1 expression, indicating that this response is not cell-
type dependent. These findings indicate that MUC1 promotes
growth arrest and survival in the response to DNA damage.
MUC1 regulates the p53-dependent growth arrest and
apoptotic responses to DNA damage in HCT116 cells
To determine if the effects of MUC1 on growth arrest and sur-
vival are dependent on p53, HCT116/p53−/− cells (Bunz et al.,
1998) were transfected to express an empty vector or MUC1.
Immunoblot analysis of two separately isolated HCT116/
p53−/−/MUC1 clones confirmed expression of MUC1 N-ter and
C-ter at levels similar to that in HCT116/MUC1 cells (Figure
7A). As controls, immunoblotting was also performed on ly-171
A R T I C L EFigure 5. MUC1 regulates activation of the p21-Luc and Bax-Luc reporters
A: HCT116/vector (open bars) and HCT116/MUC1 cells (solid bars) were
transfected with the p21-Luc reporter (left) or the Bax promoter-Luc repor-
ter (right). At 24 hr after transfection, the cells were left untreated or
treated with 10 M CDDP or etoposide for 24 hr and then assayed for
luciferase activity. The results are expressed as the fold activation (mean ±
SD of 3 separate experiments) compared to that obtained with untreated
HCT116/vector cells (assigned a value of 1). Similar results were obtained
with the separately isolated HCT116/vector-B and HCT116/MUC1-B cells
(data not shown).
B: ZR-75-1/MUC1siRNA (open bars) and ZR-75-1/vector (solid bars) cells
were transfected with p21-Luc (left) or Bax-Luc (right), incubated for 24 hr,
and then treated with 10 M CDDP or etoposide for 24 hr. Luciferase activ-
ity is presented as the fold activation (mean ± SD of 3 separate experi-
ments) compared to that obtained with untreated ZR-75-1/MUC1siRNA
cells (assigned a value of 1).
C and D: The indicated cells were left untreated or treated with 50 or 100
M cisplatin (left) or etoposide (right) for 24 hr. Lysates were analyzed by
immunoblotting with the indicated antibodies.172Figure 6. MUC1 activates the G1 growth arrest response to DNA damage
A: HCT116/vector (,) and HCT116/MUC1 (■) cells treated with 25 M cis-
platin (left) or 12.5 M etoposide (right) for the indicated times were ana-
lyzed by flow cytometry. The results are presented as the percentage
(mean ± SD of three separate experiments) of cells in G1 phase.
B: ZR-75-1/vector (:) and ZR-75-1/MUC1siRNA (O) cells treated with 25 M
cisplatin (left) or 12.5 M etoposide (right) for the indicated times were
analyzed by flow cytometry. The results are presented as the percentage
(mean ± SD of three separate experiments) of cells in G1 phase.
C: HCT116/vector (,) and HCT116/MUC1 (■) cells were treated with 50
M cisplatin or etoposide for the indicated times. The cells were then incu-
bated in the absence of drug for 8 days and stained with crystal violet.
Results are expressed as the number (mean ± SD of three separate experi-
ments) of colonies.
D: ZR-75-1/vector (:) and ZR-75-1/MUC1siRNA (O) cells were treated with
50 M cisplatin or etoposide for the indicated times. The cells were then
incubated in the absence of drug for 8 days and stained with crystal violet.
Results are expressed as the number (mean ± SD of three separate experi-
ments) of colonies.sates from HCT116 and HCT116/p53−/− cells stably trans-
fected with the empty vector (Figure 7A). Importantly, and in
contrast to HCT116/MUC1 cells, MUC1 occupancy of the
p53REs in the p21 promoter was undetectable in HCT116/CANCER CELL : FEBRUARY 2005
A R T I C L EFigure 7. MUC1 regulates the p53-dependent, DNA damage-induced
growth arrest and apoptotic responses in HCT116 cells
A: HCT116/p53−/− cells were transfected to stably express MUC1. Lysates
from two independently selected HCT116/p53−/−/MUC1 clones were sub-
jected to immunoblotting with the indicated antibodies. Lysates from
HCT116/vector, HCT116/p53−/−/vector, and HCT116/MUC1 cells were in-
cluded as controls.
B: Soluble chromatin from the indicated cells was immunoprecipitated
with anti-MUC1 C-ter and analyzed for p21 p53RE and Bax PP sequences.
C: HCT116/p53−/−/vector (open bars) and HCT116/p53−/−/MUC1 cells (solid
bars) were transfected with the p21-Luc (left) or Bax-Luc (right) reporter. At
24 hr after transfection, the cells were left untreated or treated with 10 MCANCER CELL : FEBRUARY 2005p53 (Figure 8D), while MUC1 suppressed Bax expression inde-
cisplatin or etoposide for 24 hr and then assayed for luciferase activity.
The results are expressed as the fold activation (mean ± SD of 3 separate
experiments) compared to that obtained with untreated HCT116/p53−/−/
vector cells (assigned a value of 1). Similar results were obtained with the
separately isolated HCT116/p53−/−/MUC1 clones (data not shown).
D: The indicated cells were left untreated or treated with 100 M cisplatin
(left) or etoposide (right) for 24 hr. Lysates were analyzed by immunoblot-
ting with the indicated antibodies.
E: MUC1-negative HCT116/vector and HCT116/p53−/−/vector cells (open
bars) or MUC1-positive HCT116/MUC1 and HCT116/ p53−/−/MUC1 (solid
bars) cells were treated with 25 M cisplatin or 12.5 M etoposide for 48 hr
and analyzed by flow cytometry (Supplemental Figure S3A). The results are
presented as the percentage (mean ± SD of three separate experiments)
of cells in G1 phase.
F: MUC1-negative HCT116/vector and HCT116/p53−/−/vector cells (open
bars) or MUC1-positive HCT116/MUC1 and HCT116/ p53−/−/MUC1 (solid
bars) cells were treated with 50 M cisplatin or 25 M etoposide for 72 hr
and analyzed by flow cytometry (Supplemental Figure S3B and S3C). The
results are presented as the percentage (mean ± SD of three separate
experiments) of cells with sub-G1 DNA.p53−/−/MUC1 cells (Figure 7B), indicating that association of
MUC1 with these p53REs is dependent on p53. In contrast,
the absence of p53 in HCT116/p53−/−/MUC1 cells had little
effect on MUC1 C-ter occupancy of the Bax proximal promoter
(Figure 7B). Similar results were obtained with the two indepen-
dently isolated HCT116/p53−/−/MUC1 cell clones and in the re-
sponse to DNA damage (data not shown). In addition, com-
pared to HCT116/MUC1 cells (Figure 5A, left), the effects of
MUC1 on DNA damage-induced activation of p21-Luc were
substantially decreased in HCT116/p53−/−/MUC1 cells (Figure
7C, left). Conversely, MUC1 was as effective in suppressing
Bax-Luc expression in both HCT116/MUC1 (Figure 5A, right)
and HCT116/p53−/−/MUC1 cells (Figure 7C, right). Consistent
with these results, the effects of MUC1 on DNA damage-
induced expression of p21 were p53-dependent, while sup-
pression of Bax by MUC1 was independent of p53 (Figure 7D).
The effects of MUC1 on DNA damage-induced growth arrest
were also dependent on p53 (Supplemental Figure S3A and
Figure 7E). The results further demonstrate that MUC1 attenu-
ates p53-dependent, as well as p53-independent, apoptosis in
response to DNA damage (Supplemental Figures S3B and S3C
and Figure 7F).
MUC1 silencing attenuates the p53-dependent growth
arrest response and increases the p53-dependent
apoptotic response to DNA damage in ZR-75-1 cells
p53 was knocked down in the ZR-75-1/vector and ZR-75-1/
MUC1siRNA cells by infection with an adenovirus expressing
a p53siRNA (Ad.p53siRNA) (Figure 8A). Knocking down p53
reduced MUC1 occupancy of the p53REs in the p21 promoter
(Figure 8B), consistent with a p53-dependent mechanism.
However, knocking down p53 had little effect on MUC1 occu-
pancy of the Bax proximal promoter (Figure 8B). In addition,
MUC1 increased DNA damage-induced p21-Luc activation in
ZR-75-1 cells by a p53-dependent mechanism (Figure 8C, left,
compared to Figure 5B, left). Moreover, MUC1-mediated sup-
pression of Bax-Luc was similar in ZR-75-1 cells with basal
(Figure 5B, right) or knocked down (Figure 8C, right) levels of
p53 expression. The effects of MUC1 on DNA damage-
induced expression of p21 were attenuated in the absence of173
A R T I C L EFigure 8. Silencing MUC1 in ZR-75-1 cells attenuates the p53-dependent
growth arrest response and potentiates the p53-dependent apoptotic re-
sponse to DNA damage
A: ZR-75-1/vector and ZR-75-1/MUC1siRNA cells were infected with a con-
trol empty adenovirus or one expressing a p53siRNA (Ad.p53siRNA) for 48
hr. Lysates were analyzed by immunoblotting with the indicated anti-
bodies.
B: Soluble chromatin from the indicated cells was immunoprecipitated
with anti-MUC1 C-ter and analyzed for p21 p53RE and Bax PP sequences.174to induction of an apoptotic or growth arrest response (Khar-
C: ZR-75-1/MUC1siRNA (open bars) and ZR-75-1/vector cells (solid bars)
were infected with Ad.p53siRNA for 24 hr and then transfected with the
p21-Luc (left) or Bax-Luc (right) reporter. At 24 hr after transfection, the cells
were left untreated or treated with 10 M cisplatin or etoposide for 24 hr
and then assayed for luciferase activity. The results are expressed as the
fold activation (mean ± SD of 3 separate experiments) compared to that
obtained with untreated ZR-75-1/MUC1siRNA/Ad.p53siRNA cells (assigned
a value of 1). Similar results were obtained with the separately isolated
ZR-75-1/vector and ZR-75-1/MUC1siRNA clones infected with Ad.p53siRNA
(data not shown).
D: ZR-75-1/MUC1siRNA and ZR-75-1/vector cells infected with Ad.p53siRNA
for 48 hr were left untreated or treated with 100 M cisplatin (left) or etopo-
side (right) for 24 hr. Lysates were analyzed by immunoblotting with the
indicated antibodies.
E: ZR-75-1/MUC1siRNA and ZR-75-1/MUC1siRNA/Ad.p53siRNA cells (open
bars) or ZR-75-1/vector and ZR-75-1/vector/Ad.p53siRNA (solid bars) were
treated with 25 M cisplatin or 12.5 M etoposide for 48 hr and analyzed
by flow cytometry (Supplemental Figure S4A). The results are presented
as the percentage (mean ± SD of three separate experiments) of cells in
G1 phase.
F: ZR-75-1/MUC1siRNA and ZR-75-1/MUC1siRNA/Ad.p53siRNA cells (open
bars) or ZR-75-1/vector and ZR-75-1/vector/Ad.p53siRNA (solid bars) were
treated with 50 M cisplatin or 25 M etoposide for 72 hr and analyzed by
flow cytometry (Supplemental Figures S4B and S4C). The results are pre-
sented as the percentage (mean ± SD of three separate experiments) of
cells with sub-G1 DNA.pendently of changes in p53 levels (Figure 8D). In concert with
these results, MUC1 potentiated DNA damage-induced growth
arrest in large part by a p53-dependent mechanism (Supple-
mental Figure S4A and Figure 8E). MUC1 also blocked p53-
dependent and p53-independent apoptosis in the response of
ZR-75-1 cells to DNA damage (Supplemental Figures S4B and
S4C and Figure 8F).
Discussion
MUC1 interacts directly with p53
The MUC1 heterodimer is aberrantly overexpressed in the cy-
tosol and on the entire cell membrane of diverse human carci-
nomas (Kufe et al., 1984; Perey et al., 1992). The MUC1 C-ter-
minal subunit also localizes to the nucleus and mitochondria
(Li et al., 2003a, 2003b, 2003c; Ren et al., 2004; Wen et al.,
2003). However, the mechanisms responsible for disassocia-
tion of the MUC1 subunits, and whether this occurs in the ER,
cytosol, and cell membrane, are presently not known. The pre-
sent studies demonstrate that MUC1 C-ter, and not N-ter, in-
teracts with p53. Binding of MUC1 and p53 was detectable
constitutively and increased in the response to DNA damage.
The results also demonstrate that MUC1 is detectable with p53
on promoters of the p53-responsive p21 and Bax genes.
MUC1 does not contain a prototypical nuclear localization sig-
nal (NLS) and, as such, does not bind to importin α (unpub-
lished data). However, like other proteins without a NLS that
enter the nucleus (Kau et al., 2004), MUC1 does bind to impor-
tin β (unpublished data). Our results indicate that a region of
the MUC1 cytoplasmic tail (amino acids 9–46) functions as a
site for direct binding to the p53 regulatory domain. Ref-1
binds to the p53 regulatory domain and enhances p53 DNA
binding activity (Jayaraman et al., 1997). Activation of c-Abl by
genotoxic agents is associated with binding of c-Abl to the p53
regulatory domain and, depending on cell context, contributesCANCER CELL : FEBRUARY 2005
A R T I C L Ebanda et al., 1995; Nie et al., 2000; Yuan et al., 1996, 1997).
Binding of the p53 regulatory domain to the Werner syndrome
protein also activates p53-mediated apoptosis (Blander et al.,
1999; Spillare et al., 1999). Conversely, binding of the BRCA1
protein to the p53 regulatory domain induces cell cycle arrest
(MacLachlan et al., 2002). These findings indicated that binding
of MUC1 to the p53 regulatory domain might also contribute
to cell fate selection in the p53 response to stress.
MUC1 coactivates p21 gene transcription
Chromatin-bound p53 is present at similar extents on genes
that control apoptosis or growth arrest during induction of both
responses (Kaeser and Iggo, 2002; Szak et al., 2001), indicat-
ing that selective binding of p53 to a promoter is not per se a
determinant for choice of cell fate. Consistent with these find-
ings, recruitment of the transcriptional coactivators p300/CBP
and hADA3 has been shown to dictate selective activation of
p53 target genes, including p21 (Dumaz and Meek, 1999; Es-
pinosa and Emerson, 2001; Lambert et al., 1998; Wang et al.,
2001). The present results demonstrate that MUC1 is detecta-
ble with p53 on the p53REs in the p21 promoter and that
MUC1 occupancy of these elements is increased by DNA dam-
age and dependent on p53 (Supplemental Figure S5). In addi-
tion, the finding that MUC1 coactivates p21 transcription can
be explained, at least in part, by MUC1-induced recruitment of
CBP and not HDAC1 to the p21 promoter (Supplemental Fig-
ure S5). Binding of CBP to p53 is necessary for histone acety-
lation (Barlev et al., 2001) and p53-mediated activation of p21
transcription (Liu et al., 2003; Mujtaba et al., 2004). In this re-
gard, MUC1-induced recruitment of CBP to the p21 promoter
was associated with increased acetylation of histone H4. More-
over, MUC1 expression was associated with activation of both
the p21 promoter-Luc reporter and the endogenous p21 gene
in the response to genotoxic stress. These findings indicate
that the interaction between MUC1 and p53 contributes to the
recruitment of CBP and thereby activation of p21 transcription.
MUC1 attenuates activation of the Bax gene
in response to DNA damage
Binding of p53 to the Bax promoter in cells is lower compared
with the p21 promoter (Kaeser and Iggo, 2002). The present
studies demonstrate that, in contrast to the p21 promoter,
there is no detectable MUC1 occupancy of the p53-responsive
element in the Bax promoter (Supplemental Figure S5). There
was also no detectable MUC1 binding to the Bax p53RE after
DNA damage. Surprisingly, however, we found that MUC1 pre-
cipitates with the Bax proximal promoter, and that this associa-
tion is increased by DNA damage. Coprecipitation of MUC1
with TBP further indicated that MUC1 occupies the region of
the Bax proximal promoter that includes the basal transcription
complex (Supplemental Figure S5). Notably, p53 interacts with
TBP on certain genes (Chang et al., 1995; Farmer et al., 1996;
Horikoshi et al., 1995; Liu et al., 1993; Seto et al., 1992) and
was detectable with MUC1 on the Bax proximal promoter, sug-
gesting that MUC1 may be targeted to this region by a p53-
dependent mechanism. However, decreases in p53 levels had
little effect on MUC1 occupancy of the Bax proximal promoter.
Thus, like p53, MUC1 may also associate with basal transcrip-
tion factors. In this context, MUC1 occupancy of the Bax proxi-
mal promoter had no apparent effect on TBP, but decreased
occupancy by TFIIB and TAFII250 (Supplemental Figure S5).CANCER CELL : FEBRUARY 2005Moreover, MUC1 expression was associated with attenuation
of Bax gene activation by a p53-independent mechanism, and
derepression of the Bax promoter in the absence of MUC1 was
observed in both p53-positive and p53-negative cells. The
findings with p21 and Bax thus indicate that MUC1 selectively
regulates transcription of p53-responsive genes by DNA dam-
age-induced binding of MUC1 in a promoter-specific manner.
MUC1 is of functional importance in regulation of the
p53-dependent growth arrest and apoptotic responses
Our results demonstrate that MUC1 promotes the growth ar-
rest response to DNA damage by a mechanism dependent on
p53. MUC1 also suppressed p53-dependent and p53-inde-
pendent apoptotic responses to DNA damage. MUC1 attenu-
ates DNA damage-induced activation of the intrinsic apoptotic
pathway by a mechanism that is at least in part due to its mito-
chondrial localization (Ren et al., 2004). Thus, MUC1 may block
apoptosis that is p53-dependent or p53-independent by sup-
pressing both Bax activation and the release of apoptogenic
factors from mitochondria. MUC1 also interacts with β-catenin
and GSK3β, effectors of the antiapoptotic canonical Wnt sig-
naling pathway (Li et al., 1998; Yamamoto et al., 1997). Cross-
talk exists between p53 and β-catenin signaling (Damalas et
al., 1999, 2001; Sadot et al., 2001), and MUC1 may function in
integrating these pathways. In this regard, DNA damage de-
creases the interaction between MUC1 and β-catenin (unpub-
lished data) and, as shown in the present work, increases bind-
ing of MUC1 and p53. Coimmunoprecipitation studies indicate
that MUC1 forms independent complexes with β-cate-
nin and with p53 (unpublished data). However, it is not pres-
ently known if the same pool of MUC1 interacts with these
proteins. Further studies will be needed to determine if MUC1
attenuates stress-induced apoptosis by participating in both
p53- and β-catenin-dependent pathways.
Does the MUC1-p53 interaction contribute
to a physiologic defense mechanism
exploited by human tumors?
MUC1 functions in providing a protective barrier against dam-
age to the apical borders of epithelial cells. The MUC1 cyto-
plasmic tail also signals environmental stress at the apical
membrane to the interior of the cell. The epithelial stress re-
sponse is associated with loss of polarity and activation of a
heregulin-induced repair program (Vermeer et al., 2003). He-
regulin also targets MUC1 to the nucleus (Li et al., 2003c) and
mitochondria (Ren et al., 2004). Thus, under physiologic condi-
tions, stress-induced nuclear and mitochondrial targeting of
MUC1 could contribute to a transient p53-mediated growth ar-
rest response, suppression of Bax activation, and attenuation
of the intrinsic apoptotic pathway. With transformation and loss
of polarity, MUC1 is constitutively expressed in the nucleus and
mitochondria (Li et al., 2003b, 2003c; Ren et al., 2004). Thus,
human tumors that overexpress MUC1 may have a survival ad-
vantage to genotoxic and potentially other forms of stress by
exploiting physiologic mechanisms that evolved for the repair
of damaged epithelia.
Experimental procedures
Cell culture
Human HCT116/vector, HCT116/MUC1 (Ren et al., 2002b), HCT116/p53−/−
(Bunz et al., 1998), and human MCF-7 breast cancer cells were grown in175
A R T I C L EDulbecco’s modified Eagle’s medium with 10% heat-inactivated fetal bo-
vine serum (HI-FBS), 100 g/ml streptomycin, 100 units/ml penicillin, and
2 mM L-glutamine. Human ZR-75-1 breast and human LNCaP prostate car-
cinoma cells were cultured in RPMI 1640 medium supplemented with 10%
HI-FBS, antibiotics, and L-glutamine. Human U2OS osteosarcoma cells
were grown in minimal essential medium with 10% HI-FBS and antibiotics.
Cells were treated with cisplatin (CDDP; Sigma) or etoposide (Sigma).
Immunoblotting and immunoprecipitation
Lysates were prepared from subconfluent cells as described (Wei et al.,
2003). Immunoblot analysis was performed with anti-p53 (Ab-2, Ab-6; On-
cogene Research Products), anti-MUC1 N-ter (DF3) (Kufe et al., 1984),
anti-MUC1 C-ter (Ab-5; Neomarkers, Freemont, CA), anti-β-actin (Sigma),
anti-Myc (Ab-1; Oncogene Research Products), anti-Bax (Santa Cruz Bio-
technology), and anti-p21 (Santa Cruz Biotechnology). Lysates were also
subjected to immunoprecipitation with anti-p53 or anti-Myc, and the im-
mune complexes were analyzed by immunoblotting.
Plasmid construction and transfection
MUC1-CD (1–72) and deletions thereof were generated by PCR using pIRE-
Spuro2-MUC1 as a template (Li et al., 2001a). To generate vectors express-
ing GST-MUC1-CD, the PCR products were digested with BamHI/NotI and
cloned into corresponding sites of pGEX-4T-3. Transfections were per-
formed in 60 mm dishes using Fugene-6 (Roche Applied Science) or, for the
luciferase assays, in 24-well plates using the calcium phosphate method
(Invitrogen). Cells were transfected with the p21 (2.4 kbp HindII fragment)-
Luc reporter (Ren et al., 2002a) or the Bax promoter (370 bp SmaI/SacI
fragment)-luciferase (Luc) reporter (Miyashita and Reed, 1995) and an in-
ternal control LacZ expression plasmid (pCMV-LacZ) (Wei et al., 2001). Lu-
ciferase assays were performed with the Luciferase Assay System (Pro-
mega Corp.) at 40 hr after transfection. Luciferase activity was normalized
to that obtained for LacZ and presented as relative luciferase activity.
HCT116/p53−/− cells were stably transfected with pIRES-puro-2 or pIRES-
puro-2-MUC1 as described (Ren et al., 2004).
GST pulldown assays
GST and GST fusion proteins were purified by binding to glutathione-agar-
ose beads (Sigma). 35S-labeled p53 prepared in TNT reactions (Promega
Corp.) was incubated with GST or the GST fusion proteins for 90 min at
4°C. After washing, the adsorbed proteins were resolved by SDS-PAGE and
analyzed by autoradiography or Coomassie blue staining.
Chromatin immunoprecipitation (ChIP) and Re-ChIP assays
ChIP assays were performed as described (Shang et al., 2000) using anti-
MUC1 C-ter, anti-p53 (Ab-6; Oncogene Research Products), anti-CBP (C-1;
Santa Cruz Biotechnology), anti-HDAC1 (Upstate Biotechnology Inc.), anti-
Ac-H4 (Upstate Biotechnology Inc.), anti-TBP (58C9; Santa Cruz Biotech-
nology), anti-TFIIB (IIB8; Santa Cruz Biotechnology), or anti-TAFII250 (6B3;
Santa Cruz Biotechnology). For Re-ChIP assays, complexes from the pri-
mary ChIP were eluted with 10 mM DTT for 30 min at 37°C and diluted 20
times with Re-ChIP buffer (20 mM Tris-HCl [pH 8.1], 1% Triton X-100, 2 mM
EDTA, 150 mM NaCl), followed by reimmunoprecipitation with the indicated
second antibodies, and subjected again to the ChIP procedure. For PCR,
2 l from a 50 l DNA extraction were used with 30–38 cycles of amplifica-
tion. The primers for the p21 promoter p53-responsive elements (p53RE1
and p53RE2) have been described (Liu et al., 2003). The primers for the
p21 control region (CR) were (5#-GGTGCTTCTGGGAGAGGTGAC; 3#-TGA
CCCACTCTGGCAGGCAAG) and for the p21 proximal promoter (PP) were
(5#-GGAAGTGCCCTCCTGCAGCAC; 3#-CGGCGAATCCGCGCCCAGCTC).
Primers used for the Bax promoter p53RE were (5#-GATTGGGCCAC
TGCACTCCAG; 3#-TGACTAAAAACTGAGTGG), for the Bax control region
(CR) were (5#-CCTGCTGATCTATCAGCACAG; 3#-GCTGGTCTCTGAACT
CCCAGA), and for the Bax proximal promoter (PP) were (5#-CGTGGGCTA
TATTGCTAGATC; 3#-GTCCAATCGCAGCTCTAATGC).
Flow cytometry
Cells were fixed with 80% ice-cold ethanol, incubated in PBS containing
30 g/ml RNase (Roche Applied Science) for 60 min at 37°C, and then
stained with propidium iodide (Sigma) for 30 min at room temperature in176the dark. DNA content was analyzed by flow cytometry (Coulter EPICS
XL-MCL).
Colony formation assays
Aliquots containing 500 cells/well were plated onto 6-well plates containing
2 ml/well complete medium and incubated for 18–24 hr at 37°C. The cells
were treated with CDDP or etoposide for 12–48 hr, washed, and incubated
for 8 days. Resulting colonies were stained with crystal violet and counted
manually.
Apoptosis assays
Apoptotic cells were quantitated by analysis of sub-G1 DNA and propidium
iodide staining as described (Ren et al., 2004).
Downregulation of p53
ZR-75-1/vector and ZR-75-1/MUC1siRNA cells were seeded (5 × 105/well)
on 6-well plates. After 24 hr, the cells were infected with an empty adenovi-
rus or one expressing human p53 siRNA (2 × 109 Ad.p53siRNA particles/
well; IMGENEX, San Diego, CA). The cells were incubated for 48–72 hr and
then harvested for analysis.
Supplemental data
Supplemental data for this article can be found at http://www.cancercell.
org/cgi/content/full/7/2/167/DC1/.
Acknowledgments
This work was supported by grants CA097098 and CA29431 awarded by
the National Cancer Institute and grant BC022158 awarded by the US Army.
The authors acknowledge Kamal Chauhan for excellent technical support.
Received: June 15, 2004
Revised: November 30, 2004
Accepted: January 19, 2005
Published: February 14, 2005
References
Asada, M., Yamada, T., Ichijo, H., Delia, D., Miyazono, K., Fukumuro, K.,
and Mizutani, S. (1999). Apoptosis inhibitory activity of cytoplasmic
p21(Cip1/WAF1) in monocytic differentiation. EMBO J. 18, 1223–1234.
Barlev, N.A., Liu, L., Chehab, N.H., Mansfield, K., Harris, K.G., Halazonetis,
T.D., and Berger, S.L. (2001). Acetylation of p53 activates transcription
through recruitment of coactivators/histone acetyltransferases. Mol. Cell 8,
1243–1254.
Blander, G., Kipnis, J., Leal, J.F., Yu, C.E., Schellenberg, G.D., and Oren, M.
(1999). Physical and functional interaction between p53 and the Werner's
syndrome protein. J. Biol. Chem. 274, 29463–29469.
Bunz, F., Dutriaux, A., Lengauer, C., Waldman, T., Zhou, S., Brown, J.P.,
Sedivy, J.M., Kinzler, K.W., and Vogelstein, B. (1998). Requirement for p53
and p21 to sustain G2 arrest after DNA damage. Science 282, 1497–1501.
Chang, J., Kim, D.H., Lee, S.W., Choi, K.Y., and Sung, Y.C. (1995). Transacti-
vation ability of p53 transcriptional activation domain is directly related to
the binding affinity to TATA-binding protein. J. Biol. Chem. 270, 25014–
25019.
Chao, C., Saito, S., Kang, J., Anderson, C.W., Appella, E., and Xu, Y. (2000).
p53 transcriptional activity is essential for p53-dependent apoptosis follow-
ing DNA damage. EMBO J. 19, 4967–4975.
Damalas, A., Ben-Ze'ev, A., Simcha, I., Shtutman, M., Leal, J.F., Zhurinsky,
J., Geiger, B., and Oren, M. (1999). Excess beta-catenin promotes accumu-
lation of transcriptionally active p53. EMBO J. 18, 3054–3063.
Damalas, A., Kahan, S., Shtutman, M., Ben-Ze'ev, A., and Oren, M. (2001).
Deregulated beta-catenin induces a p53- and ARF-dependent growth arrest
and cooperates with Ras in transformation. EMBO J. 20, 4912–4922.CANCER CELL : FEBRUARY 2005
A R T I C L EDong, Y., Chi, S.L., Borowsky, A.D., Fan, Y., and Weiss, R.H. (2004). Cyto-
solic p21Waf1/Cip1 increases cell cycle transit in vascular smooth muscle
cells. Cell. Signal. 16, 263–269.
Dumaz, N., and Meek, D.W. (1999). Serine15 phosphorylation stimulates
p53 transactivation but does not directly influence interaction with HDM2.
EMBO J. 18, 7002–7010.
Dupont, J., Karas, M., and LeRoith, D. (2003). The cyclin-dependent kinase
inhibitor p21CIP/WAF is a positive regulator of insulin-like growth factor
I-induced cell proliferation in MCF-7 human breast cancer cells. J. Biol.
Chem. 278, 37256–37264.
El-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent,
J.M., Lin, D., Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1,
a potential mediator of p53 tumor suppression. Cell 75, 817–825.
Espinosa, J.M., and Emerson, B.M. (2001). Transcriptional regulation by p53
through intrinsic DNA/chromatin binding and site-directed cofactor recruit-
ment. Mol. Cell 8, 57–69.
Espinosa, J.M., Verdun, R.E., and Emerson, B.M. (2003). p53 functions
through stress- and promoter-specific recruitment of transcription initiation
components before and after DNA damage. Mol. Cell 12, 1015–1027.
Farmer, G., Colgan, J., Nakatani, Y., Manley, J.L., and Prives, C. (1996).
Functional interaction between p53, the TATA-binding protein (TBP), and
TBP-associated factors in vivo. Mol. Cell. Biol. 16, 4295–4304.
Flores, E.R., Tsai, K.Y., Crowley, D., Sengupta, S., Yang, A., McKeon, F., and
Jacks, T. (2002). p63 and p73 are required for p53-dependent apoptosis in
response to DNA damage. Nature 416, 560–564.
Gendler, S., Taylor-Papadimitriou, J., Duhig, T., Rothbard, J., and Burchell,
J.A. (1988). A highly immunogenic region of a human polymorphic epithelial
mucin expressed by carcinomas is made up of tandem repeats. J. Biol.
Chem. 263, 12820–12823.
Horikoshi, N., Usheva, A., Chen, J., Levine, A.J., Weinmann, R., and Shenk,
T. (1995). Two domains of p53 interact with the TATA-binding protein, and
the adenovirus 13S E1A protein disrupts the association, relieving p53-
mediated transcriptional repression. Mol. Cell. Biol. 15, 227–234.
Hsieh, J.K., Yap, D., O'Connor, D.J., Fogal, V., Fallis, L., Chan, F., Zhong,
S., and Lu, X. (2002). Novel function of the cyclin A binding site of E2F in
regulating p53-induced apoptosis in response to DNA damage. Mol. Cell.
Biol. 22, 78–93.
Huang, L., Ren, J., Chen, D., Li, Y., Kharbanda, S., and Kufe, D. (2003).
MUC1 cytoplasmic domain coactivates Wnt target gene transcription and
confers transformation. Cancer Biol. Ther. 2, 702–706.
Jack, M.T., Woo, R.A., Hirao, A., Cheung, A., Mak, T.W., and Lee, P.W.
(2002). Chk2 is dispensable for p53-mediated G1 arrest but is required for
a latent p53-mediated apoptotic response. Proc. Natl. Acad. Sci. USA 99,
9825–9829.
Jayaraman, L., Murthy, K.G., Zhu, C., Curran, T., Xanthoudakis, S., and
Prives, C. (1997). Identification of redox/repair protein Ref-1 as a potent
activator of p53. Genes Dev. 11, 558–570.
Jimenez, G.S., Nister, M., Stommel, J.M., Beeche, M., Barcarse, E.A.,
Zhang, X.Q., O'Gorman, S., and Wahl, G.M. (2000). A transactivation-defi-
cient mouse model provides insights into Trp53 regulation and function.
Nat. Genet. 26, 37–43.
Kaeser, M.D., and Iggo, R.D. (2002). Chromatin immunoprecipitation analy-
sis fails to support the latency model for regulation of p53 DNA binding
activity in vivo. Proc. Natl. Acad. Sci. USA 99, 95–100.
Kau, T.R., Way, J.C., and Silver, P.A. (2004). Nuclear transport and cancer:
From mechanism to intervention. Nat. Rev. Cancer 4, 106–117.
Kharbanda, S., Ren, R., Pandey, P., Shafman, T.D., Feller, S.M., Weichsel-
baum, R.R., and Kufe, D.W. (1995). Activation of the c-Abl tyrosine kinase
in the stress response to DNA-damaging agents. Nature 376, 785–788.
Kufe, D., Inghirami, G., Abe, M., Hayes, D., Justi-Wheeler, H., and Schlom,
J. (1984). Differential reactivity of a novel monoclonal antibody (DF3) with
human malignant versus benign breast tumors. Hybridoma 3, 223–232.
Lambert, P.F., Kashanchi, F., Radonovich, M.F., Shiekhattar, R., and Brady,CANCER CELL : FEBRUARY 2005J.N. (1998). Phosphorylation of p53 serine 15 increases interaction with
CBP. J. Biol. Chem. 273, 33048–33053.
Levine, A.J. (1997). p53, the cellular gatekeeper for growth and division.
Cell 88, 323–331.
Li, Y., Bharti, A., Chen, D., Gong, J., and Kufe, D. (1998). Interaction of
glycogen synthase kinase 3β with the DF3/MUC1 carcinoma-associated
antigen and β-catenin. Mol. Cell. Biol. 18, 7216–7224.
Li, Y., Kuwahara, H., Ren, J., Wen, G., and Kufe, D. (2001a). The c-Src
tyrosine kinase regulates signaling of the human DF3/MUC1 carcinoma-
associated antigen with GSK3β and β-catenin. J. Biol. Chem. 276, 6061–
6064.
Li, Y., Ren, J., Yu, W.-H., Li, G., Kuwahara, H., Yin, L., Carraway, K.L., and
Kufe, D. (2001b). The EGF receptor regulates interaction of the human DF3/
MUC1 carcinoma antigen with c-Src and β-catenin. J. Biol. Chem. 276,
35239–35242.
Li, Y., Chen, W., Ren, J., Yu, W., Li, Q., Yoshida, K., and Kufe, D. (2003a).
DF3/MUC1 signaling in multiple myeloma cells is regulated by interleukin-
7. Cancer Biol. Ther. 2, 187–193.
Li, Y., Liu, D., Chen, D., Kharbanda, S., and Kufe, D. (2003b). Human DF3/
MUC1 carcinoma-associated protein functions as an oncogene. Oncogene
22, 6107–6110.
Li, Y., Yu, W.-H., Ren, J., Huang, L., Kharbanda, S., Loda, M., and Kufe,
D. (2003c). Heregulin targets γ-catenin to the nucleolus by a mechanism
dependent on the DF3/MUC1 protein. Mol. Cancer Res. 1, 765–775.
Ligtenberg, M.J., Kruijshaar, L., Buijs, F., van Meijer, M., Litvinov, S.V., and
Hilkens, J. (1992). Cell-associated episialin is a complex containing two
proteins derived from a common precursor. J. Biol. Chem. 267, 6171–6177.
Liu, X., Miller, C.W., Koeffler, P.H., and Berk, A.J. (1993). The p53 activation
domain binds the TATA box-binding polypeptide in Holo-TFIID, and a neigh-
boring p53 domain inhibits transcription. Mol. Cell. Biol. 13, 3291–3300.
Liu, G., Xia, T., and Chen, X. (2003). The activation domains, the proline-
rich domain, and the C-terminal basic domain in p53 are necessary for
acetylation of histones on the proximal p21 promoter and interaction with
p300/CREB-binding protein. J. Biol. Chem. 278, 17557–17565.
MacLachlan, T.K., Takimoto, R., and El-Deiry, W.S. (2002). BRCA1 directs a
selective p53-dependent transcriptional response towards growth arrest
and DNA repair targets. Mol. Cell. Biol. 22, 4280–4292.
Merlo, G., Siddiqui, J., Cropp, C., Liscia, D.S., Lidereau, R., Callahan, R.,
and Kufe, D. (1989). DF3 tumor-associated antigen gene is located in a
region on chromosome 1q frequently altered in primary human breast can-
cer. Cancer Res. 49, 6966–6971.
Miyashita, T., and Reed, J.C. (1995). Tumor suppressor p53 is a direct tran-
scriptional activator of the human bax gene. Cell 80, 293–299.
Mujtaba, S., He, Y., Zeng, L., Yan, S., Plotnikova, O., Sanchez, R., Zeleznik-
Le, N.J., Ronai, Z., and Zhou, M.M. (2004). Structural mechanism of the
bromodomain of the coactivator CBP in p53 transcriptional activation. Mol.
Cell 13, 251–263.
Muller, M., Wilder, S., Bannasch, D., Israeli, D., Lehlbach, K., Li-Weber, M.,
Friedman, S.L., Galle, P.R., Stremmel, W., Oren, M., and Krammer, P.H.
(1998). p53 activates the CD95 (APO-1/Fas) gene in response to DNA dam-
age by anticancer drugs. J. Exp. Med. 188, 2033–2045.
Nie, Y., Li, H., Bula, C., and Liu, X. (2000). Stimulation of p53 DNA binding
by c-Abl requires the p53 C terminus and tetramerization. Mol. Cell. Biol.
20, 741–748.
Oda, E., Ohki, R., Murasawa, H., Nemoto, J., Shibue, T., Yamashita, T.,
Tokino, T., Taniguchi, T., and Tanaka, N. (2000a). Noxa, a BH3-only member
of the Bcl-2 family and candidate mediator of p53-induced apoptosis. Sci-
ence 288, 1053–1058.
Oda, K., Arakawa, H., Tanaka, T., Matsuda, K., Tanikawa, C., Mori, T., Nishi-
mori, H., Tamai, K., Tokino, T., Nakamura, Y., and Taya, Y. (2000b). p53AIP1,
a potential mediator of p53-dependent apoptosis, and its regulation by Ser-
46-phosphorylated p53. Cell 102, 849–862.177
A R T I C L EOren, M. (2003). Decision making by p53: Life, death and cancer. Cell Death
Differ. 10, 431–442.
Perey, L., Hayes, D.F., Maimonis, P., Abe, M., O'Hara, C., and Kufe, D.W.
(1992). Tumor selective reactivity of a monoclonal antibody prepared
against a recombinant peptide derived from the DF3 human breast carci-
noma-associated antigen. Cancer Res. 52, 2563–2568.
Ren, J., Datta, R., Shioya, H., Li, Y., Oki, E., Biedermann, V., Bharti, A., and
Kufe, D. (2002a). p73β is regulated by protein kinase Cδ catalytic fragment
generated in the apoptotic response to DNA damage. J. Biol. Chem. 277,
33758–33765.
Ren, J., Li, Y., and Kufe, D. (2002b). Protein kinase C δ regulates function
of the DF3/MUC1 carcinoma antigen in β-catenin signaling. J. Biol. Chem.
277, 17616–17622.
Ren, J., Agata, N., Chen, D., Li, Y., Yu, W.-H., Huang, L., Raina, D., Chen,
W., Kharbanda, S., and Kufe, D. (2004). Human MUC1 carcinoma-associ-
ated protein confers resistance to genotoxic anti-cancer agents. Cancer
Cell 5, 163–175.
Sadot, E., Geiger, B., Oren, M., and Ben-Ze'ev, A. (2001). Down-regulation
of beta-catenin by activated p53. Mol. Cell. Biol. 21, 6768–6781.
Samuels-Lev, Y., O'Connor, D.J., Bergamaschi, D., Trigiante, G., Hsieh, J.K.,
Zhong, S., Campargue, I., Naumovski, L., Crook, T., and Lu, X. (2001). ASPP
proteins specifically stimulate the apoptotic function of p53. Mol. Cell 8,
781–794.
Schroeder, J., Thompson, M., Gardner, M., and Gendler, S. (2001). Trans-
genic MUC1 interacts with epidermal growth factor receptor and correlates
with mitogen-activated protein kinase activation in the mouse mammary
gland. J. Biol. Chem. 276, 13057–13064.
Schroeder, J.A., Masri, A.A., Adriance, M.C., Tessier, J.C., Kotlarczyk, K.L.,
Thompson, M.C., and Gendler, S.J. (2004). MUC1 overexpression results in
mammary gland tumorigenesis and prolonged alveolar differentiation. On-
cogene 23, 5739–5747.
Seto, E., Usheva, A., Zambett, G., Momand, J., Horikoshi, R., Weinmann,
A., Levine, J., and Shenk, T. (1992). Wild-type p53 binds to the TATA-binding
protein and represses transcription. Proc. Natl. Acad. Sci. USA 89,
12028–12032.
Shang, Y., Hu, X., DiRenzo, J., Lazar, M.A., and Brown, M. (2000). Cofactor
dynamics and sufficiency in estrogen receptor-regulated transcription. Cell
103, 843–852.
Shikama, N., Lee, C., France, S., Delavaine, L., Lyon, J., Krstic-Demonacos,
M., and La Thangue, N. (1999). A novel cofactor for p300 that regulates the
p53 response. Mol. Cell 4, 365–376.
Siddiqui, J., Abe, M., Hayes, D., Shani, E., Yunis, E., and Kufe, D. (1988).
Isolation and sequencing of a cDNA coding for the human DF3 breast carci-
noma-associated antigen. Proc. Natl. Acad. Sci. USA 85, 2320–2323.
Spillare, E.A., Robles, A.I., Wang, X.W., Shen, J.C., Yu, C.E., Schellenberg,
G.D., and Harris, C.C. (1999). p53-mediated apoptosis is attenuated in Wer-
ner syndrome cells. Genes Dev. 13, 1355–1360.
Szak, S.T., Mays, D., and Pietenpol, J.A. (2001). Kinetics of p53 binding to
promoter sites in vivo. Mol. Cell. Biol. 21, 3375–3386.178Vermeer, P.D., Einwalter, L.A., Moninger, T.O., Rokhlina, T., Kern, J.A.,
Zabner, J., and Welsh, M.J. (2003). Segregation of receptor and ligand regu-
lates activation of epithelial growth factor receptor. Nature 422, 322–326.
Vousden, K.H., and Lu, X. (2002). Live or let die: The cell's response to p53.
Nat. Rev. Cancer 2, 594–604.
Wahl, G.M., and Carr, A.M. (2001). The evolution of diverse biological re-
sponses to DNA damage: Insights from yeast and p53. Nat. Cell Biol. 3,
E277–E286.
Wang, T., Kobayashi, T., Takimoto, R., Denes, A.E., Snyder, E.L., el-Deiry,
W.S., and Brachmann, R.K. (2001). hADA3 is required for p53 activity.
EMBO J. 20, 6404–6413.
Wei, L.N., Farooqui, M., and Hu, X. (2001). Ligand-dependent formation of
retinoid receptors, receptor-interacting protein 140 (RIP140), and histone
deacetylase complex is mediated by a novel receptor-interacting motif of
RIP140. J. Biol. Chem. 276, 16107–16112.
Wei, X., Yu, Z.K., Ramalingam, A., Grossman, S.R., Yu, J.H., Bloch, D.B.,
and Maki, C.G. (2003). Physical and functional interactions between PML
and MDM2. J. Biol. Chem. 278, 29288–29297.
Weiss, R.H. (2003). p21Waf1/Cip1 as a therapeutic target in breast and
other cancers. Cancer Cell 4, 425–429.
Wen, Y., Caffrey, T., Wheelock, M., Johnson, K., and Hollingsworth, M.
(2003). Nuclear association of the cytoplasmic tail of MUC1 and β-catenin.
J. Biol. Chem. 278, 38029–38039.
Wu, G.S., Burns, T.F., McDonald, E.R., 3rd, Jiang, W., Meng, R., Krantz, I.D.,
Kao, G., Gan, D.D., Zhou, J.Y., Muschel, R., et al. (1997). KILLER/DR5 is a
DNA damage-inducible p53-regulated death receptor gene. Nat. Genet. 17,
141–143.
Yamamoto, M., Bharti, A., Li, Y., and Kufe, D. (1997). Interaction of the DF3/
MUC1 breast carcinoma-associated antigen and β-catenin in cell adhesion.
J. Biol. Chem. 272, 12492–12494.
Yin, L., and Kufe, D. (2003). Human MUC1 carcinoma antigen regulates
intracellular oxidant levels and the apoptotic response to oxidative stress.
J. Biol. Chem. 278, 35458–35464.
Yin, L., Huang, L., and Kufe, D. (2004). MUC1 oncoprotein activates the
FOXO3a transcription factor in a survival response to oxidative stress. J.
Biol. Chem. 279, 45721–45727.
Yu, J., Zhang, L., Hwang, P.M., Kinzler, K.W., and Vogelstein, B. (2001).
PUMA induces the rapid apoptosis of colorectal cancer cells. Mol. Cell 7,
673–682.
Yuan, Z., Huang, Y., Fan, M., Sawers, C., Kharbanda, S., and Kufe, D.
(1996). Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and
the tumor suppressor protein p53. J. Biol. Chem. 271, 26457–26460.
Yuan, Z., Huang, Y., Ishiko, T., Kharbanda, S., Weichselbaum, R., and Kufe,
D. (1997). Regulation of DNA damage-induced apoptosis by the c-Abl tyro-
sine kinase. Proc. Natl. Acad. Sci. USA 94, 1437–1440.
Zhang, C., Kavurma, M.M., Lai, A., and Khachigian, L.M. (2003). Ets-1 pro-
tects vascular smooth muscle cells from undergoing apoptosis by activating
p21WAF1/Cip1: ETS-1 regulates basal and inducible p21WAF1/Cip1 tran-
scription via distinct cis-acting elements in the p21WAF/Cip1 promoter. J.
Biol. Chem. 278, 27903–27909.CANCER CELL : FEBRUARY 2005
